You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Beyond Clinical Trials: What Does Real-World Evidence Tell Us About COVID-19 mRNA Vaccine Effectiveness and Safety?

  • Authors: Huldrych Günthard, MD; Matteo Bassetti, MD, PhD; Philip Haaf, MD
  • CPD Released: 1/18/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 1/18/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for a non-US audience of primary care physicians, infectious diseases specialists, pediatricians, pharmacists, and nurses.

The goal of this activity is to improve knowledge about real-world data on safety and effectiveness for COVID-19 messenger ribonucleic acid (mRNA) vaccines. 

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial evidence of efficacy and safety of mRNA vaccines
    • Effectiveness and safety data of mRNA vaccines from real-world studies


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Moderator

  • Huldrych Günthard, MD

    Professor for Infectious Diseases  
    Deputy Director  
    Department for Infectious Diseases and Hospital Epidemiology 
    University Hospital Zurich  
    Zurich, Switzerland 

    Disclosures

    Disclosure: Huldrych Günthard, MD, has the following relevant financial relationships:
    Advisor or consultant for: Gilead Sciences; Merck Sharp & Dohme Corp; ViiV Healthcare 
    Grants for clinical research from: Gilead Sciences

Faculty

  • Matteo Bassetti, MD, PhD

    Professor of Infectious Diseases
    Department of Health Science
    University of Genoa
    Head, Infectious Diseases Clinic
    Hospital Policlinico San Martino – IRCCS
    Genoa, Italy

    Disclosures

    Disclosure: Matteo Bassetti, MD, PhD, has the following relevant financial relationships: 
    Advisor or consultant for: Angelini; Cidara; Menarini; Merck Sharp & Dohme; Pfizer Inc.; Roche; Shionogi 
    Speaker or a member of a speakers bureau for: Angelini; Astellas; Bayer; bioMérieux; Cidara; Cipla; Gilead Sciences; Menarini; Merck Sharp & Dohme; Pfizer Inc.; Shionogi 
    Grants for clinical research from: Gilead; Merck Sharp & Dohme; Pfizer Inc. 

  • Philip Haaf, MD

    Department of Cardiology
    Cardiovascular Research Institute Basel
    University Hospital Basel
    University of Basel
    Basel, Switzerland

    Disclosures

    Philip Haaf, MD, has disclosed no relevant financial relationships. 

Steering Committee

  • Paolo Bonanni, MD

    Professor of Hygiene
    Faculty of Medicine
    Director
    Department of Health Sciences
    University of Florence
    Florence, Italy

    Disclosures

    Disclosure: Paolo Bonanni, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Janssen Pharmaceuticals; Merck Sharp & Dohme Corp; Pfizer Inc.; Sanofi Pasteur; Seqirus
    Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Merck Sharp & Dohme Corp; Pfizer Inc.; Sanofi Pasteur; Seqirus
    Received grants for clinical research from: GlaxoSmithKline; Merck Sharp & Dohme Corp; Pfizer Inc.; Sanofi Pasteur; Seqirus

  • Federico Martinón-Torres, MD, PhD

    Head of Pediatrics
    Director of Translational Pediatrics and Infectious Diseases
    Hospital Clínico Universitario de Santiago
    Associate Professor in Pediatrics
    University of Santiago de Compostela
    Galicia, Spain

    Disclosures

    Disclosure: Federico Martinón-Torres, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Ablynx; AstraZeneca Pharmaceuticals LP; Biofabri; GlaxoSmithKline; Janssen Pharmaceuticals; Merck & Co., Inc.; Merck Sharp & Dohme Corp; Novavax, Inc.; Pfizer Inc.; Roche; Sanofi Pasteur; Seqirus
    Served as a speaker or a member of a speakers bureau for: Ablynx; AstraZeneca Pharmaceuticals LP; Biofabri; GlaxoSmithKline; Janssen Pharmaceuticals; Merck & Co., Inc.; Merck Sharp & Dohme Corp; Novavax, Inc.; Pfizer Inc.; Roche; Sanofi Pasteur; Seqirus
    Received grants for clinical research from: GlaxoSmithKline; Merck & Co., Inc./Merck Sharp & Dohme Corp; Pfizer Inc.
    Other – PI on clinical trials: Abbott Laboratories; Ablynx; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Janssen Pharmaceuticals; MedImmune Inc.; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Sanofi Pasteur; Seqirus

  • George Kassianos, CBE, MD (Hons), FRCGP

    General Practitioner, National Immunization Lead
    Royal College of General Practitioners
    President, British Global and Travel Health Association
    London, United Kingdom

    Disclosures

    Disclosure: George Kassianos, CBE, MD (Hons), FRCGP, has disclosed no relevant financial relationships.

  • Ravindra Gupta, MD, PhD

    Professor of Clinical Microbiology
    Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge
    Cambridge, United Kingdom

    Disclosures

    Disclosure: Ravindra Gupta, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: GlaxoSmithKline; ViiV Healthcare
    Served as a speaker or a member of a speakers bureau for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Received grants for clinical research from: Wellcome

  • Barbara Rath, MD, PhD

    Co-Founder and Chair
    The Vienna Vaccine Safety Initiative
    Research Director, Université de Bourgogne Franche-Comté
    Besançon, France

    Disclosures

    Disclosure: Barbara Rath, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Atriva; AstraZeneca; GlaxoSmithKline; Roche

  • Karine Lacombe, MD, PhD

    Professor of Infectious Diseases
    Sorbonne University 
    Head of Infectious and Tropical Diseases Department
    Saint-Antoine Hospital
    Inserm, Institut Pierre Louis de Santé Publique
    Paris, France

    Disclosures

    Disclosure: Karine Lacombe, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Chiesi Pharmaceuticals; GlaxoSmithKline; Merck; Sobi; SpikImm

  • Saul N. Faust, FRCPCH, PhD

    Professor of Paediatric Immunology and Infectious Diseases
    Director
    NIHR Southampton Clinical Research Facility
    University Hospital Southampton NHS Foundation Trust
    and University of Southampton
    Southampton, United Kingdom

    Disclosures

    Disclosure: Saul N. Faust, FRCPCH, PhD, has disclosed the following relevant financial relationships: 
    Served as an advisor or consultant for: GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer Inc.; Sanofi; Seqirus 
    Served as a speaker or a member of a speakers bureau for: Johnson & Johnson; Pfizer Inc. 
    Received grants for clinical research from: AstraZeneca; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer Inc.; Sanofi; Valneva 

  • Philip Haaf, MD

    As listed above

Editors

  • Shanthi Voorn, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships. 

  • Diana Lucifero, PhD

    Scientific Content Manager, WebMD Global, LLC 

    Disclosures

    Disclosure: Diana Lucifero, PhD, has disclosed no relevant financial relationships. 

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Beyond Clinical Trials: What Does Real-World Evidence Tell Us About COVID-19 mRNA Vaccine Effectiveness and Safety?

Authors: Huldrych Günthard, MD; Matteo Bassetti, MD, PhD; Philip Haaf, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 1/18/2022

Valid for credit through: 1/18/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to improve knowledge about real-world data on safety and effectiveness for COVID-19 messenger ribonucleic acid (mRNA) vaccines.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print